CDR2 and ovarian carcinoma: In Yo-PCD ovarian carcinomas, a high percentage of the tumors were found to harbor at least one genetic alteration of Yo antigens which was not observed in ovarian carcinoma samples extracted from patients without Yo-PCD (120).